Truepoint Inc. grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 27.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,982 shares of the company’s stock after purchasing an additional 429 shares during the quarter. Truepoint Inc.’s holdings in Johnson & Johnson were worth $277,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in the company. Goodman Financial Corp bought a new position in Johnson & Johnson during the 4th quarter worth approximately $104,000. Price Wealth Management Inc. bought a new position in Johnson & Johnson during the 4th quarter worth approximately $148,000. Roble Belko & Company Inc grew its position in Johnson & Johnson by 59.7% during the 4th quarter. Roble Belko & Company Inc now owns 1,164 shares of the company’s stock worth $163,000 after acquiring an additional 435 shares during the last quarter. Cerebellum GP LLC bought a new position in Johnson & Johnson during the 4th quarter worth approximately $166,000. Finally, Legacy Advisors LLC bought a new position in Johnson & Johnson during the 3rd quarter worth approximately $202,000. Hedge funds and other institutional investors own 67.40% of the company’s stock.
Several equities analysts recently issued reports on the company. Stifel Nicolaus reduced their price target on Johnson & Johnson from $145.00 to $135.00 and set a “hold” rating on the stock in a research report on Wednesday, April 18th. Jefferies Group set a $161.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research report on Friday, March 23rd. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $145.00 price target on the stock in a research report on Wednesday, April 11th. Leerink Swann reiterated an “outperform” rating and issued a $160.00 price objective (down from $175.00) on shares of Johnson & Johnson in a research report on Wednesday, April 18th. They noted that the move was a valuation call. Finally, Citigroup cut their price objective on Johnson & Johnson from $146.00 to $134.00 and set a “neutral” rating on the stock in a research report on Monday, April 23rd. Five research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $142.23.
Johnson & Johnson opened at $124.24 on Friday, according to Marketbeat.com. The company has a market capitalization of $332.28 billion, a PE ratio of 17.02, a PEG ratio of 1.90 and a beta of 0.74. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.58 and a quick ratio of 1.25. Johnson & Johnson has a 52 week low of $121.28 and a 52 week high of $148.32.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.06. The company had revenue of $20.01 billion during the quarter, compared to analysts’ expectations of $19.50 billion. Johnson & Johnson had a return on equity of 30.65% and a net margin of 1.58%. The firm’s revenue for the quarter was up 12.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.83 EPS. research analysts expect that Johnson & Johnson will post 8.13 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 12th. Stockholders of record on Tuesday, May 29th will be paid a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date is Friday, May 25th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.84. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.03%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.